https://www.selleckchem.com/pr....oducts/hmpl-504-azd6
BACKGROUND Limited evidence has indicated that addition of a steroidal mineralocorticoid receptor antagonist (MRA) to the standard of care reduces proteinuria in patients with diabetic kidney disease (DKD); however, there are limited data regarding real-world MRA use in these patients. This study aimed to describe the characteristics of spironolactone users and non-users with DKD, and to explore their clinical outcomes. METHODS This was a non-interventional, retrospective cohort study using demographic and clinical da
Like
Comment
Share
